Cullinan Therapeutics (CGEM) Operating Income (2021 - 2023)
Historic Operating Income for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$45.5 million.
- Cullinan Therapeutics' Operating Income fell 3949.03% to -$45.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$191.1 million, marking a year-over-year decrease of 23210.62%. This contributed to the annual value of -$196.9 million for FY2024, which is 305.09% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Operating Income of -$45.5 million as of Q4 2023, which was down 3949.03% from -$45.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Operating Income ranged from a high of $239.7 million in Q2 2022 and a low of -$62.8 million during Q1 2023
- Moreover, its 3-year median value for Operating Income was -$32.6 million (2022), whereas its average is -$9.5 million.
- Examining YoY changes over the last 5 years, Cullinan Therapeutics' Operating Income showed a top increase of 154350.16% in 2022 and a maximum decrease of 248024.78% in 2022.
- Quarter analysis of 3 years shows Cullinan Therapeutics' Operating Income stood at -$34.3 million in 2021, then grew by 5.06% to -$32.6 million in 2022, then plummeted by 39.49% to -$45.5 million in 2023.
- Its last three reported values are -$45.5 million in Q4 2023, -$45.2 million for Q3 2023, and -$37.6 million during Q2 2023.